Global Surgical Sealants Market - Strategic Insights and Forecasts (2025-2030)

The Global Surgical Sealants Market is expected to grow from USD 2.1 billion in 2025 to USD 3.2 billion in 2030, at a CAGR of 9.6%.

The Surgical Sealants Market is a rapidly evolving segment of the medical device industry, driven by the increasing demand for advanced wound closure solutions that enhance patient outcomes and streamline surgical procedures. Surgical sealants, encompassing biocompatible sealants and bioresorbable adhesives, are specialized biomaterials designed to seal incisions, control bleeding, and promote tissue healing during and after surgeries. Unlike traditional wound closure methods, these sealants offer unique advantages, such as reduced infection risk, faster healing, and improved cosmetic outcomes, making them integral to modern surgical practice. The market growth is fueled by technological advancements, growing surgical volumes, and a shift toward minimally invasive procedures, positioning it as a critical component of healthcare innovation.

The surgical sealants market is experiencing significant growth due to several key drivers. First, the rise in minimally invasive surgeries, such as laparoscopic and robotic-assisted procedures, necessitates precise and efficient sealing solutions. Biocompatible sealants, like polyethylene glycol (PEG) hydrogels and fibrin-based products, provide effective hemostasis and tissue adhesion, reducing complications in procedures like cardiovascular and orthopedic surgeries. For instance, Ethicon’s VISTASEAL Fibrin Sealant has been widely adopted for managing bleeding in complex surgeries. Second, the increasing prevalence of chronic diseases, such as cardiovascular disorders and cancer, drives surgical volumes, boosting demand for sealants. The World Health Organization reports that approximately 235 million major surgical procedures are performed annually, underscoring the need for advanced wound closure solutions. Third, product innovation is accelerating market expansion, with companies developing bioresorbable adhesives that degrade naturally, eliminating the need for removal. Ethicon introduced Ethizia, a hemostatic sealing patch, enhancing outcomes in thoracic and abdominal surgeries.

Regulatory approvals play a pivotal role in market growth, with agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) streamlining pathways for innovative sealants. For example, RevBio received FDA authorization for a first-in-human clinical trial of Tetranite, a synthetic, osteoconductive bone adhesive for cranial flap fixation, highlighting the regulatory support for clinical trials in advancing sealant technologies. Similarly, the FDA’s Pre-Market Approval (PMA) of LiquiBandFix8 for hernia surgery demonstrates the market’s momentum. These approvals foster confidence among manufacturers and healthcare providers, driving the adoption of biocompatible sealants across diverse applications.

Despite its growth, the surgical sealants market faces notable restraints. High development and manufacturing costs for advanced sealants, particularly bioresorbable adhesives, limit accessibility, especially in cost-sensitive regions. The complex production of biocompatible sealants, requiring rigorous testing and clinical trials, increases expenses, often restricting market entry to well-funded companies. Additionally, stringent regulatory approvals can delay product launches, as seen with the extensive safety and efficacy data required for FDA clearance, which can take years. Competition from sutures and staples, which are more affordable and familiar to surgeons, also poses a challenge, particularly in developing economies where cost considerations outweigh innovation.

Comparison with Sutures and Staples

Surgical sealants offer distinct advantages over traditional sutures and staples, transforming wound closure practices. Sutures, typically made from materials like nylon or silk, and staples, often stainless steel, are mechanical methods that physically hold tissues together. While effective, they can cause tissue trauma, require removal in non-absorbable forms, and carry infection risks due to puncture sites. Sutures and staples are also time-consuming to apply in complex surgeries and may leave visible scars, impacting cosmetic outcomes. In contrast, biocompatible sealants, such as fibrin and PEG-based adhesives, form a hemostatic barrier that seals tissues without mechanical stress, reducing blood loss and infection risk. For example, fibrin sealants, derived from blood components, mimic natural clotting processes, promoting faster healing, as seen in Grifols’ phase 3b trial for pediatric surgeries.

Bioresorbable adhesives like Tetranite degrade naturally, eliminating the need for removal and minimizing long-term complications, unlike non-absorbable sutures and staples. Sealants are particularly advantageous in minimally invasive procedures, where precise application via sprays or gels enhances efficiency, as demonstrated by Sanyo Chemical’s Aquabrid, approved in Taiwan for central circulatory system hemostasis. However, sutures and staples remain cost-effective and widely trusted, with established use in high-tension wounds where sealants may lack sufficient tensile strength. Additionally, sealants require specialized training for optimal application, unlike the more familiar sutures and staples, which can slow adoption in resource-limited settings.

Recent industry developments highlight the market’s dynamism. For instance, Ethicon acquired GATT Technologies’ synthetic polymer platform to enhance its hemostatic portfolio, reflecting a trend toward strategic acquisitions. Similarly, Toray Industries and ASKA Pharmaceuticals’ collaboration to commercialize an adhesion barrier in Japan underscores global efforts to expand sealant applications. The surgical sealants market is poised for continued growth, driven by product innovation, supportive regulatory approvals, and the shift toward patient-centric care. As clinical trials validate new formulations, such as peptide-based adhesives for chronic wound management, the market will further redefine surgical practices, offering safer, faster, and more effective wound closure solutions.

Surgical Sealants Market Trends

1. Fibrin, Hydrogel, and Cyanoacrylate Innovations
   The Surgical Sealants Market is advancing rapidly, driven by innovations that enhance wound closure and surgical outcomes. Fibrin sealants, derived from human or animal blood components, dominate due to their biocompatibility and hemostatic properties, as seen in Ethicon’s VISTASEAL, widely used in cardiovascular surgeries. Hydrogel sealants, such as polyethylene glycol-based products, are gaining traction for their flexibility and strength in minimally invasive surgery. For instance, RevBio’s Tetranite, a hydrogel sealant approved for clinical trials, supports cranial flap fixation. Cyanoacrylate adhesives offer rapid bonding for skin closure, with LiquiBandFix8 approved for hernia repairs, enhancing laparoscopic adhesives applications. Collagen-based sealants, like CollPlant’s plant-derived solutions, are advancing wound healing in orthopedic and spinal surgeries, with trials launched recently. Polyethylene glycol (PEG) sealants provide robust tissue adhesion, exemplified by Ethizia’s hemostatic patch for thoracic procedures. These surgical sealant trends reflect a shift toward bioresorbable adhesives that reduce complications and improve recovery in minimally invasive surgery, positioning the market for sustained growth.

Surgical Sealants Market Dynamics

Market Drivers:

• Rise in Minimally Invasive Surgery Driving Demand for Laparoscopic Adhesives: The surge in minimally invasive surgery is a key driver for the surgical sealants market, as these procedures require precise, efficient wound closure solutions. Laparoscopic adhesives, such as fibrin sealants and hydrogel sealants, provide effective hemostasis and tissue sealing in procedures like laparoscopic cholecystectomy and hernia repair, reducing complications and recovery time. For instance, Ethicon’s VISTASEAL Fibrin Sealant, widely used in minimally invasive surgery, enhances outcomes in thoracic and abdominal procedures. The global increase in laparoscopic and robotic-assisted surgeries, driven by patient demand for less invasive options with better cosmetic results, fuels the adoption of biocompatible sealants. These sealants support complex surgeries by minimizing blood loss and infection risk, aligning with advancements in surgical sealant trends and driving market growth through increased surgical volumes and technological integration.

• Product Innovation in Bioresorbable Adhesives: Product innovation is propelling the surgical sealants market, particularly through the development of bioresorbable adhesives that degrade naturally, eliminating the need for removal and reducing long-term complications. Innovations like RevBio’s Tetranite, a synthetic bone adhesive approved for clinical trials, demonstrate enhanced osteoconductivity for cranial flap fixation. Similarly, Ethicon’s Ethizia, a hemostatic sealing patch, offers robust tissue adhesion for thoracic surgeries. These bioresorbable adhesives, often based on PEG sealants or collagen-based sealants, improve patient outcomes by supporting tissue regeneration and minimizing foreign body reactions. Product innovation attracts cell & gene therapy investments and fosters collaboration, as seen in Ethicon’s acquisition of GATT Technologies’ synthetic polymer platform, driving market expansion by addressing diverse surgical needs with tailored, biocompatible solutions.

• Supportive Regulatory Approvals Accelerating Market Entry: Regulatory approvals are a critical driver for the surgical sealants market, as streamlined pathways enable faster commercialization of innovative products. The U.S. FDA and European Medicines Agency (EMA) have prioritized biocompatible sealants, with approvals like LiquiBandFix8 for hernia surgery and Sanyo Chemical’s Aquabrid for central circulatory system hemostasis. The FDA’s Pre-Market Approval (PMA) and 510(k) pathways facilitate clinical trials, ensuring safety and efficacy, as seen in Grifols’ phase 3b trial for pediatric fibrin sealant applications. These approvals enhance market confidence, encouraging investment and adoption of advanced sealants. Supportive regulations, combined with growing surgical demand, accelerate the integration of bioresorbable adhesives and hydrogel sealants into clinical practice, driving market growth across cardiovascular, orthopedic, and general surgery applications.

Market Restraints:

• High Costs of Developing Biocompatible Sealants: The high cost of developing and manufacturing biocompatible sealants significantly restrains the surgical sealants market. Producing advanced sealants, such as fibrin sealants and PEG sealants, requires sophisticated processes, including biomaterial synthesis and extensive clinical trials to ensure safety and efficacy. For example, the development of bioresorbable adhesives like Tetranite involves costly testing for biocompatibility and degradation profiles, limiting accessibility in resource-constrained healthcare systems. These expenses restrict market entry to large companies like Baxter and Ethicon, reducing competition and slowing innovation. High costs also challenge reimbursement models, as healthcare providers grapple with the expense of adopting novel sealants over cost-effective sutures and staples, particularly in developing regions, hindering widespread adoption and market growth.

• Competition from Traditional Sutures and Staples: The surgical sealants market faces significant competition from traditional sutures and staples, which are more affordable and familiar to surgeons. Sutures, made from materials like nylon, and staples, typically stainless steel, offer reliable tensile strength for high-tension wounds, such as in orthopedic or trauma surgeries, where cyanoacrylate adhesives or hydrogel sealants may fall short. Their lower cost and established use, especially in developing economies, limit the adoption of advanced sealants. For instance, sutures and staples require minimal training compared to sealants, which demand specialized application techniques. This familiarity, combined with cost advantages, slows the transition to biocompatible sealants, particularly in regions with budget constraints, posing a persistent restraint on market expansion despite the superior benefits of sealants in minimally invasive surgery.

Surgical Sealants Market Segmentation Analysis

• By Form: Biological Biological sealants dominate the surgical sealants market due to their superior biocompatibility and ability to mimic natural tissue healing processes, making them ideal for a wide range of surgical applications. Derived from natural sources like human or animal blood components or plant-based materials, biological sealants, such as fibrin sealants and collagen-based sealants, promote hemostasis and tissue adhesion while minimizing adverse reactions. For example, Ethicon’s VISTASEAL Fibrin Sealant, widely used in cardiovascular surgery and general surgery, leverages fibrinogen and thrombin to form a clot-like seal, enhancing outcomes in complex procedures. Similarly, CollPlant’s plant-derived collagen-based sealants are advancing orthopedic surgery and wound healing, with clinical trials approved for spinal cord injury treatments. Biological sealants are favored for their bioresorbable properties, degrading naturally without requiring removal, which aligns with surgical sealant trends toward patient-centric, minimally invasive solutions.

• By Type: Fibrin Sealants Fibrin Sealants lead the surgical sealants market due to their versatility, rapid hemostatic action, and widespread adoption in minimally invasive surgery. Composed of fibrinogen and thrombin, these sealants mimic the body’s natural clotting mechanism, providing effective bleeding control and tissue adhesion. Ethicon’s VISTASEAL, used in cardiovascular surgery and pulmonary surgery, exemplifies its efficacy in managing intraoperative bleeding. Grifols’ phase 3b trial further validated fibrin sealants for pediatric surgeries, highlighting their safety across diverse patient groups. Their biocompatible nature and ability to integrate with laparoscopic adhesives make them critical in procedures requiring precision, such as neurological surgery. Fibrin sealants benefit from supportive regulatory approvals, like the FDA’s clearance for expanded indications, driving their dominance in the market as they address the growing demand for reliable, bioresorbable adhesives in complex surgical settings.

• By Application: Cardiovascular Surgery Cardiovascular Surgery is the leading application in the surgical sealants market, driven by the high volume of procedures and the critical need for effective hemostasis in complex operations like coronary artery bypass grafting and valve repair. Fibrin sealants and PEG hydrogels are extensively used to seal vascular anastomoses and control bleeding, improving patient outcomes. For instance, Sanyo Chemical’s Aquabrid, approved in Taiwan, provides hemostasis in central circulatory system surgeries, showcasing the role of biocompatible sealants. The increasing prevalence of cardiovascular diseases, coupled with advancements in minimally invasive surgery, fuels demand for sealants that offer rapid, reliable tissue sealing without compromising vascular integrity. Cardiovascular surgery benefits from ongoing clinical trials and product innovation, such as Ethicon’s Ethizia sealing patch, enhancing the market’s growth by addressing critical surgical challenges.

Surgical Sealants Market Key Developments

List of major companies: Baxter International Inc., Becton, Dickinson and Company, CollPlant Biotechnologies Ltd., CryoLife, Inc., CSL Limited

• Product Launch: In December 2024, H.B. Fuller is expected to finalize the acquisition of GEM S.r.l. and Medifill Ltd. This strategic move is set to significantly expand H.B. Fuller's Medical Adhesive Technologies (MAT) business. GEM S.r.l. is an Italian manufacturer of medical adhesives for over 80 internal indications, while Medifill Ltd. is an Irish formulator and producer of medical-grade cyanoacrylate adhesives, including advanced formulations for wound closure. The acquisitions will provide H.B. Fuller with a European headquarters for its MAT business and enhance its portfolio in the high-growth surgical market.

• Product Launch: In July 2024, Corza Medical acquired the manufacturing operations for TachoSil from Takeda. TachoSil is a well-known hemostatic fibrin patch used in surgical procedures to stop bleeding and seal tissues. This acquisition allows Corza Medical to gain control over the production of a key product in the surgical sealants space, which is expected to improve its supply chain and accelerate its ability to serve key global markets. This move solidifies Corza Medical's position as a player in the surgical hemostasis and sealant field.

• Product Launch: In June 2024, Tissium, a company specializing in biomorphic programmable polymers, received FDA Breakthrough Device designation for its polymer-based tissue sealant for a specific surgical application. This designation is given to certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The development highlights a major advancement in synthetic polymer technology for surgical sealing, offering a new avenue for a safer and more effective way to manage tissue leaks during complex surgical procedures.

Surgical Sealants Market Scope: